°¨¿°Áõ Áø´Ü ½ÃÀå : Á¦Ç° ¹× ¼­ºñ½ºº°, °Ë»ç À¯Çüº°, »ùÇà À¯Çüº°, Áúȯ À¯Çüº°, ±â¼úº°, ÃÖÁ¾»ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Infectious Disease Diagnostic Market, By Product & Service, By Type of Testing, By Sample Type, By Disease Type, By Technology, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1781928
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 399 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,567,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,535,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,941,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

°¨¿°Áõ Áø´Ü ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 229¾ï 1,800¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â¿¡ CAGR 8.2%·Î È®´ë

°¨¿°º´ Áø´Ü ½ÃÀå - ½ÃÀå ¿ªÇÐ

°¨¿°¼º Áúȯ ¹ßº´·ü Áõ°¡

¼¼°è °¨¿°º´ ¹ßº´·ü Áõ°¡´Â °¨¿°º´ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀÔ´Ï´Ù. Àα¸ ¹Ðµµ Áõ°¡, ¼¼°è ¿©Çà, ±âÈÄ º¯È­ µîÀÇ ¿äÀÎÀÌ º´¿ø±ÕÀÇ ±Þ¼ÓÇÑ È®»ê¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Ç×»ýÁ¦ ³»¼º ±ÕÁÖ ¹× ½ÅÁ¾ °¨¿°º´ÀÇ ÃâÇöÀ¸·Î Á¤È®ÇÏ°í ½Å¼ÓÇÑ Áø´Ü ÅøÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¶±â¿¡ Á¤È®ÇÑ Áø´ÜÀ» ÅëÇØ Àû½Ã¿¡ Ä¡·áÇÒ ¼ö ÀÖÀ¸¸ç, Áúº´ ÀüÆÄ¸¦ ÁÙÀ̰í ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú, ÇコÄÉ¾î ½Ã½ºÅÛÀº ÷´Ü Áø´Ü ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â °¨¿°º´ °¨Áö ¹× °ü¸® ½ÃÀåÀÇ ¼ºÀå°ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

°¨¿°¼º Áúȯ Áø´Ü ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

´ç»çÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®¿¡ µû¸£¸é ¼¼°è °¨¿°º´ Áø´Ü ½ÃÀåÀº 2024-2032³â ¾à 8.2%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

2023³â Á¦Ç° ¹× ¼­ºñ½ºº°·Î´Â ½Ã¾à, ŰƮ, ¼Ò¸ðǰ Ä«Å×°í¸®°¡ ½ÃÀåÀ» Àå¾ÇÇϰí ÀÖ½À´Ï´Ù.

±â¼úº°·Î´Â ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ(PCR) ºÎ¹®ÀÌ 2023³â °¡Àå ³ôÀº ¸ÅÃâÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Áö¿ªº°·Î´Â 2023³â ºÏ¹Ì°¡ °¡Àå ³ôÀº ¸ÅÃâÀ» ¿Ã¸° Áö¿ªÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

°¨¿°º´ Áø´Ü ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼®

¼¼°è °¨¿°º´ Áø´Ü ½ÃÀåÀº Á¦Ç° ¹× ¼­ºñ½º, ÃÖÁ¾»ç¿ëÀÚ, °Ë»ç À¯Çü, »ùÇà À¯Çü, Áúº´ À¯Çü, ±â¼ú, Áö¿ª µî 7°¡Áö ¹üÁÖ·Î ºÐ·ùµË´Ï´Ù.

°¨¿°º´ Áø´Ü ½ÃÀåÀº Á¦Ç° ¹× ¼­ºñ½ºº°·Î ½Ã¾à-ŰƮ-¼Ò¸ðǰ, ±â±â, ¼ÒÇÁÆ®¿þ¾î ¼­ºñ½º µî ¼¼ °¡Áö·Î ºÐ·ùµË´Ï´Ù. ½Ã¾à, ŰƮ, ¼Ò¸ðǰ¿¡´Â Áø´Ü °Ë»ç ¼öÇà¿¡ ÇʼöÀûÀÎ È­Çй°Áú, °Ë»ç ŰƮ, Àç·á°¡ Æ÷ÇԵ˴ϴÙ. Àåºñ¶õ PCR ÀåÄ¡, ¸é¿ªÃøÁ¤ºÐ¼®±â, Çö¹Ì°æ µî Áø´Ü ÀýÂ÷¸¦ ¼öÇàÇϱâ À§ÇØ »ç¿ëµÇ´Â ÀåÄ¡³ª ±â°è¸¦ ¸»ÇÕ´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º¿¡´Â µ¥ÀÌÅÍ °ü¸® Åø, Áø´Ü ¼ÒÇÁÆ®¿þ¾î, °Ë»ç Á¤È®µµ¸¦ ³ôÀÌ°í °Ë»ç½Ç ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ´Â Áö¿ø ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ÀÌ Áß ½Ã¾à, ŰƮ, ¼Ò¸ðǰÀº ½ÇÇè½Ç°ú º´¿ø¿¡¼­ ÀÏ»óÀûÀÎ °Ë»ç¿¡ ´ëÇÑ ¹Ýº¹ÀûÀÎ ¼ö¿ä·Î ÀÎÇØ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. ³ôÀº ¼ÒºñÀ²°ú °Ë»ç Á¤È®µµ¿¡¼­ÀÇ Áß¿äÇÑ ¿ªÇÒ·Î ÀÎÇØ ÀÌ ºÎ¹®Àº °¨¿°¼º Áúȯ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ¸ÅÃâ ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

°¨¿°º´ Áø´Ü ½ÃÀåÀº ±â¼úº°·Î ¸é¿ªÁø´Ü, ÀÓ»ó¹Ì»ý¹°ÇÐ, ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR), µî¿ÂÇÙ»êÁõÆø±â¼ú, DNA ½ÃÄö½Ì ¹× Â÷¼¼´ë ½ÃÄö½Ì(NGS), DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ, ±âŸ ½ÅÈï±â¼ú·Î ºÐ·ùµË´Ï´Ù. ¸é¿ªÁø´ÜÇп¡¼­´Â °¨¿°º´À» È®ÀÎÇϱâ À§ÇØ Ç׿øÀ̳ª Ç×ü¸¦ °ËÃâÇÏ¿© °¨¿°º´À» È®ÀÎÇÕ´Ï´Ù. ÀÓ»ó¹Ì»ý¹°ÇÐÀº ¹Ì»ý¹°ÀÇ ¹è¾ç°ú µ¿Á¤¿¡ ÁßÁ¡À» µÓ´Ï´Ù. PCRÀ̳ª µî¿Â ÇÙ»êÁõÆøÀº º´¿ø±ÕÀÇ DNA³ª RNA¸¦ ÁõÆøÇÏ¿© Á¤È®ÇÏ°Ô °ËÃâÇÏ´Â ºÐÀÚ ±â¼úÀÔ´Ï´Ù. DNA ½ÃÄö½Ì°ú NGS´Â º´¿øÃ¼ ½Äº° ¹× ³»¼º ÇÁ·ÎÆÄÀϸµÀ» À§ÇÑ Á¾ÇÕÀûÀÎ À¯ÀüÀÚ Á¤º¸¸¦ Á¦°øÇϰí, DNA ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ´ë±Ô¸ð À¯ÀüÀÚ ¹ßÇö ºÐ¼®À» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ Áß ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR)Àº ³ôÀº ¹Î°¨µµ, ƯÀ̼º, ºü¸¥ ¼Ò¿ä½Ã°£, Àü ¼¼°è ÀÓ»ó ½ÇÇè½Ç¿¡¼­ ±¤¹üÀ§ÇÏ°Ô Ã¤ÅõǾî Á¤È®ÇÑ °¨¿°¼º Áúȯ °ËÃâÀ» À§ÇØ ¼±È£µÇ´Â ¼±ÅÃÀ¸·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

°¨¿°º´ Áø´Ü ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

°¨¿°º´ Áø´Ü ½ÃÀåÀº ºÏ¹Ì, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«¿¡ ºÐÆ÷µÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªµéÀº ºñÁî´Ï½º¸¦ ÃÊ·¡ÇÏ´Â ±¹°¡¸¦ ±âÁØÀ¸·Î ´õ ¼¼ºÐÈ­µË´Ï´Ù.

ºÏ¹Ì´Â ÷´ÜÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó, ³ôÀº ÀÇ·áºñ, ÷´Ü Áø´Ü ±â¼úÀÇ º¸±ÞÀ¸·Î ÀÎÇØ °¨¿°¼º Áúȯ Áø´Ü ½ÃÀå¿¡¼­ Áö¹èÀûÀÎ Áö¿ªÀÔ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ¿¬±¸°³¹ß¿¡ ´ëÇÑ ¸·´ëÇÑ ÅõÀÚ, °­·ÂÇÑ ±ÔÁ¦ Áö¿ø, ´ëÇü Áø´ÜÀǾàǰ ±â¾÷ÀÇ Á¸Àç·Î ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â Áúº´ÀÇ Á¶±â ¹ß°ß¿¡ ´ëÇÑ Á߿伺, °¨¿°¼º Áúȯ Áõ°¡, ÀÇ·á Á¾»çÀÚµéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Áø´Ü ´É·ÂÀ» Çâ»ó½Ã۱â À§ÇÑ Á¤ºÎÀÇ ±¸»ó°ú ½Å¼ÓÇÑ ÇöÀå °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡µµ ºÏ¹Ì°¡ ÀÌ ½ÃÀå¿¡¼­ ¾ÐµµÀûÀÎ À§Ä¡¸¦ Â÷ÁöÇϰí ÀÖ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸ Áõ°¡, ÀÇ·á Á¢±Ù¼º Çâ»ó, °¨¿°º´ ºÎ´ã Áõ°¡·Î ÀÎÇØ °¨¿°¼º Áúȯ Áø´Ü ÀǾàǰÀÇ ÁÖ¿ä ½ÃÀå Áß Çϳª·Î ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. Áß±¹, Àεµ¿Í °°Àº ±¹°¡µéÀº ÀÇ·á ÀÎÇÁ¶óÀÇ È®´ë¿Í ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¤ºÎ ÁöÃâ Áõ°¡·Î ¼ö¿ä¸¦ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÎ½Ä Áõ°¡, Áø´Ü ½Ã¼³ÀÇ °³¼±, ´õ ³ªÀº ÀÇ·á ¼­ºñ½º¸¦ ¿øÇÏ´Â Áß»êÃþ Áõ°¡ µîÀÇ ÇýÅÃÀ» ´©¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °áÇÙ, µ­±â¿­, COVID-19¿Í °°Àº Àü¿°º´ÀÇ ¹ß»ýÀº °­·ÂÇÑ Áø´Ü ¼Ö·ç¼ÇÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖÀ¸¸ç, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÌ ºÎ¹®¿¡¼­ ºü¸£°Ô ¼ºÀåÇÏ´Â Àü·«ÀûÀ¸·Î Áß¿äÇÑ ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

°¨¿°º´ Áø´Ü ½ÃÀå - °æÀï ±¸µµ

°¨¿°º´ Áø´Ü ½ÃÀåÀº Abbott, F. Hoffman-La Roche, Thermo Fisher Scientific, BioMerule µî ±¤¹üÀ§ÇÑ Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Áö¼ÓÀûÀÎ ±â¼ú Çõ½ÅÀ¸·Î ¿ìÀ§¸¦ Á¡Çϰí ÀÖ´Â ´ë±â¾÷ÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌµé ±â¾÷Àº ¿¬±¸°³¹ß¿¡ ¸¹Àº ÅõÀÚ¸¦ ÅëÇØ Áø´Ü Á¤È®µµ, ¼Óµµ, ÀÚµ¿È­¸¦ °­È­ÇÏ¿© ¾ö°ÝÇÑ ±ÔÁ¦ ±âÁØÀ» ÃæÁ·Çϰí ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ºÐÀÚÁø´Ü ¹× ÇöÀå °Ë»ç ±â¼ú¿¡ ÁÖ·ÂÇÏ´Â ½Å»ý ±â¾÷¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Àü·«Àû Àμö ¹× Á¦ÈÞ´Â °¢ ±â¾÷ÀÌ Áö¿ªÀû ÀÔÁö¿Í ±â¼ú ¿ª·®À» È®ÀåÇÏ°í ±Ã±ØÀûÀ¸·Î Àü ¼¼°è¿¡¼­ °¨¿°¼º ÁúȯÀÇ ¹ß°ß°ú ȯÀÚ Ä¡·á °á°ú¸¦ °³¼±Çϱâ À§ÇØ ÀϹÝÀûÀ¸·Î ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå °¨¿°Áõ Áø´Ü ½ÃÀå °³¿ä

Á¦2Àå °³¿ä

Á¦3Àå °¨¿°Áõ Áø´ÜÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå °¨¿°Áõ Áø´Ü »ê¾÷ ¿¬±¸

Á¦5Àå °¨¿°Áõ Áø´Ü ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå °¨¿°Áõ Áø´Ü ½ÃÀå ±¸µµ

Á¦7Àå °¨¿°Áõ Áø´Ü ½ÃÀå - Á¦Ç°¡¤¼­ºñ½ºº°

Á¦8Àå °¨¿°Áõ Áø´Ü ½ÃÀå - °Ë»ç À¯Çüº°

Á¦9Àå °¨¿°Áõ Áø´Ü ½ÃÀå - »ùÇà À¯Çüº°

Á¦10Àå °¨¿°Áõ Áø´Ü ½ÃÀå - Áúȯº°

Á¦11Àå °¨¿°Áõ Áø´Ü ½ÃÀå - ±â¼úº°

Á¦12Àå °¨¿°Áõ Áø´Ü ½ÃÀå - ÃÖÁ¾»ç¿ëÀÚº°

Á¦13Àå °¨¿°Áõ Áø´Ü ½ÃÀå - Áö¿ª

Á¦14Àå ÁÖ¿ä º¥´õ ºÐ¼® - °¨¿°Áõ Áø´Ü »ê¾÷

Á¦15Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Infectious Disease Diagnostic Market size was valued at USD 22,918 Million in 2024, expanding at a CAGR of 8.2% from 2024 to 2032.

Infectious Disease Diagnostic refers to the process and methods used to detect, identify, and confirm the presence of pathogens such as bacteria, viruses, fungi, or parasites that cause infectious diseases in humans or animals. This diagnostic process employs various techniques, including laboratory tests like culture, microscopy, molecular assays (e.g., PCR), antigen detection, and serology. Accurate and timely infectious disease diagnostics are crucial for appropriate treatment decisions, infection control, and epidemiological surveillance. These diagnostics help differentiate infectious agents, monitor disease progression, and guide public health interventions to prevent outbreaks and manage patient care effectively.

Infectious Disease Diagnostic Market- Market Dynamics

Growing Prevalence of Infectious Diseases

The increasing incidence of infectious diseases worldwide is a key driver for the infectious disease diagnostics market. Factors such as rising population density, global travel, and climate change contribute to the rapid spread of pathogens. Additionally, the emergence of antibiotic-resistant strains and novel infectious agents has intensified the need for accurate, rapid diagnostic tools. Early and precise diagnosis enables timely treatment, reducing disease transmission and improving patient outcomes. Consequently, healthcare systems are investing more in advanced diagnostic technologies, fueling market growth and innovation in infectious disease detection and management.

Infectious Disease Diagnostic Market- Key Insights

According to our research analyst, the global Infectious Disease Diagnostic Market is expected to develop at a CAGR of approximately 8.2% between 2024-2032.

Segmented by Product And Service in 2023, the Reagents, Kits, And Consumables category dominated the market.

Based on Technology, the Polymerase Chain Reaction (PCR) segment generated the most income in 2023.

On the basis of region, in 2023, North America was the region with the highest revenue.

Infectious Disease Diagnostic Market- Segmentation Analysis:

The global Infectious Disease Diagnostic Market is divided into Seven categories: Product & Service, End User, Type of Testing, Sample Type, Disease Type, Technology, and Region.

The infectious disease diagnostics market is segmented by product and service into three main categories: reagents, kits, and consumables; instruments; and software & services. Reagents, kits, and consumables include the essential chemicals, test kits, and materials required for conducting diagnostic tests. Instruments refer to the devices and machinery used to perform diagnostic procedures, such as PCR machines, immunoassay analyzers, and microscopes. Software & services encompass data management tools, diagnostic software, and support services that enhance test accuracy and streamline laboratory workflows. Among these segments, reagents, kits, and consumables dominate the market due to their recurring demand in laboratories and hospitals for routine testing. Their high consumption rate and critical role in test accuracy make this segment a primary revenue driver in the infectious disease diagnostics market.

The infectious disease diagnostics market is categorized by technology into several key segments: immunodiagnostics, clinical microbiology, polymerase chain reaction (PCR), isothermal nucleic acid amplification technology, DNA sequencing & next-generation sequencing (NGS), DNA microarray, and other emerging technologies. Immunodiagnostics involves detecting antigens or antibodies to identify infections. Clinical microbiology focuses on culturing and identifying microorganisms. PCR and isothermal nucleic acid amplification are molecular techniques amplifying pathogen DNA or RNA for precise detection. DNA sequencing and NGS provide comprehensive genetic information for pathogen identification and resistance profiling, while DNA microarrays enable large-scale gene expression analysis. Among these, polymerase chain reaction (PCR) dominates the market due to its high sensitivity, specificity, rapid turnaround time, and widespread adoption in clinical laboratories worldwide, making it the preferred choice for accurate infectious disease detection.

Infectious Disease Diagnostic Market- Geographical Insights

Geographically, the Infectious Disease Diagnostic Market is distributed throughout North America, Asia Pacific, Latin America, Europe, the Middle East, and Africa. These regions are further divided based on the nations bringing in business.

North America is a dominant region in the infectious disease diagnostics market, driven by advanced healthcare infrastructure, high healthcare expenditure, and widespread adoption of cutting-edge diagnostic technologies. The U.S., in particular, leads due to significant investments in research and development, strong regulatory support, and the presence of major diagnostic companies. The region's focus on early disease detection, rising prevalence of infectious diseases, and growing awareness among healthcare providers further fuel market growth. Additionally, government initiatives to improve diagnostic capabilities and the increasing demand for rapid point-of-care testing contribute to North America's commanding position in this market.

Asia Pacific is another key market for infectious disease diagnostics, experiencing rapid growth fueled by a large and growing population, increasing healthcare access, and rising infectious disease burden. Countries like China and India drive demand due to expanding healthcare infrastructure and increased government spending on healthcare services. The region benefits from rising awareness, improved diagnostic facilities, and a growing middle class seeking better healthcare. Additionally, the outbreak of infectious diseases such as tuberculosis, dengue, and COVID-19 has emphasized the need for robust diagnostic solutions, positioning Asia Pacific as a fast-growing and strategically important market in this sector.

Infectious Disease Diagnostic Market- Competitive Landscape:

The infectious disease diagnostic market is shaped by leading players such as Abbott, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and bioMerieux, which dominate through extensive product portfolios and continuous innovation. These companies invest heavily in research and development to enhance diagnostic accuracy, speed, and automation, meeting stringent regulatory standards. The competitive environment is also driven by emerging firms focusing on molecular diagnostics and point-of-care testing technologies. Strategic acquisitions and collaborations are common as companies seek to expand their geographic presence and technological capabilities, ultimately improving infectious disease detection and patient outcomes worldwide.

Recent Developments:

In March 2025, Abbott launched a new rapid molecular test for respiratory infections that delivers results in under 30 minutes, enhancing point-of-care diagnostics.

In January 2024, Roche expanded its diagnostic testing portfolio with the introduction of a highly sensitive COVID-19 and flu multiplex assay, improving simultaneous detection of multiple pathogens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT & SERVICE - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY END USER - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TYPE OF TESTING - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY SAMPLE TYPE - MARKET ANALYSIS, 2019 - 2032

GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1. Infectious Disease Diagnostic Market Overview

2. Executive Summary

3. Infectious Disease Diagnostic Key Market Trends

4. Infectious Disease Diagnostic Industry Study

5. Infectious Disease Diagnostic Market: COVID-19 Impact Analysis

6. Infectious Disease Diagnostic Market Landscape

7. Infectious Disease Diagnostic Market - By Product & Service

8. Infectious Disease Diagnostic Market - By Type of Testing

9. Infectious Disease Diagnostic Market - By Sample Type

10. Infectious Disease Diagnostic Market - By Disease Type

11. Infectious Disease Diagnostic Market - By Technology

12. Infectious Disease Diagnostic Market - By End User

13. Infectious Disease Diagnostic Market- By Geography

14. Key Vendor Analysis- Infectious Disease Diagnostic Industry

15. 360 Degree Analyst View

16. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â